Smith & Nephew plc (LON:SN) Receives Average Rating of “Hold” from Brokerages

Shares of Smith & Nephew plc (LON:SN) have received a consensus rating of “Hold” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is GBX 1,381.33.

Several research firms recently weighed in on SN. Panmure Gordon restated a “hold” rating and issued a GBX 1,200 price objective on shares of Smith & Nephew in a research report on Tuesday, December 9th. Berenberg Bank reissued a “hold” rating and issued a GBX 1,300 price target on shares of Smith & Nephew in a report on Friday, January 23rd. Royal Bank Of Canada downgraded shares of Smith & Nephew to a “sector perform” rating and dropped their price objective for the stock from GBX 1,700 to GBX 1,350 in a report on Wednesday, December 17th. Citigroup increased their target price on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th.

Insiders Place Their Bets

In other Smith & Nephew news, insider Deepak Nath sold 1,240 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total transaction of £15,586.80. 0.19% of the stock is owned by insiders.

Smith & Nephew Stock Up 2.3%

Shares of LON SN opened at GBX 1,242 on Tuesday. The business has a fifty day simple moving average of GBX 1,234.60 and a 200-day simple moving average of GBX 1,291.01. The company has a market cap of £13.62 billion, a price-to-earnings ratio of 44.72, a P/E/G ratio of 0.46 and a beta of 0.62. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.